Cannabis, marijuana and Hemp stock news from Investorideas.com plus daily cannabis #potcasts - Investor Ideas #Potcasts #Cannabis News and Stocks on the Move
Investor Ideas #Potcasts #Cannabis News and Stocks on the Move: TSX: $APHA.TO, NYSE: $APHA, TSX: $ACB.TO, NYSE: $ACB, CSE: $CXXI.C
Delta, Kelowna, BC - November 5, 2018 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today's edition of its series, Investorideas.com potcastsCM - cannabis news and stocks to watch plus insight from thought leaders and experts.
Good afternoon and welcome to another Investorideas.com Potcast - following Cannabis news, stocks to watch as well as insights from thought leaders and experts.
Today we will be looking at announcements from Aphria Inc. trading on the TSX and NYSE as APHA, Aurora Cannabis Inc. trading on the TSX and NYSE as ACB and C21 Investments Inc. trading on the CSE as CXXI.
Aphria Inc. today announced it has established an agreement with Rapid Dose Therapeutics Inc. ("RDT") that grants the Company with exclusive global preferred rights to license, manufacture, distribute and sell RDT's QuickStrip™ innovative, proprietary delivery technology for both medical and adult-use cannabis market.
The Company intends to begin production of oral thin strips at its production facilities in Leamington, Ontario in 2019.
"Aphria is excited to revolutionize the way patients and consumers integrate cannabis into their lives and to bring QuickStrip™ technology - a product unlike any other - to the cannabis market," said Jakob Ripshtein, President of Aphria. "This agreement with RDT further demonstrates Aphria's commitment to bringing advanced products and innovations that will fit the needs of every consumer. Further, the QuickStrip™ technology will help ease concerns surrounding consumption by providing a product that delivers a consistent and precise dosage form."
RDT's proprietary QuickStrip™ technology is a Quick, Convenient, Precise, Discreet™ oral fast-dissolving drug delivery system that offers a smoke-free choice to consumers.
Aphria is a shareholder of RDT, having acquired 7,200,000 shares in a non-brokered private placement completed in August 2018 at a price of $0.75 per share for total gross proceeds of $5,400,000, representing approximately a 9.7% interest in the company.
Aurora Cannabis Inc. announced the official opening of its latest elite, high-tech cannabis production facility in Lachute, Quebec, known to the world as Aurora "Eau."
At 48,000 square feet, with 11 purpose-built grow rooms, Aurora Eau will produce up to 4,500 kg of high quality cannabis per year, all in a facility with some of the lowest electricity costs in North America. It is designed to grow niche varieties of cannabis for the premium medical and adult consumer use markets in Quebec, Canada and around the world. Eau becomes Aurora's second production facility in Quebec, the first being Aurora Vie, a 40,000 square foot indoor grow facility in Pointe Claire, Quebec.
"We're thrilled to officially open our latest technologically advanced facility in the Lachute Region and proud to continue to invest in Quebec," said Terry Booth, CEO of Aurora. "There is incredible potential at Aurora Eau. It's designed to be a place where our expert cannabis cultivators have the flexibility and control to produce some very special high-end varieties that few commercial growers are prepared to tackle. We intend to make some very rare and exciting products there."
Designed and built to meet strict European Union GMP standards and built mainly by local contractors, Aurora Eau is expected to create more than 100 full-time jobs for local area residents. For future development, it has additional manufacturing suites, which allow for increased value-add production. Throughout the construction phase of the project, Aurora injected more than $12 million into the regional community and will continue to support its economic development in coming years, playing a key role in growing the local economy. The facility is strategically located on 46 acres of land, which allows for significant future expansion potential.
C21 Investments Inc. has announced that it has entered into definitive agreements for the July 9, 2018 announced acquisition of Swell Companies Limited. Swell is an extraction, manufacturer and distributor of THC and CBD products. Swell has more than 50 of its branded products available in over 275 licensed retail locations across Oregon. Raw oil, encapsulates and vaporizers are distributed under its in-house brands: Dab Society Extracts and Hood Oil. The capacity of Swell's Portland processing facility will reach up to 5,000 lbs of raw material throughput a month. This throughput will translate into 220,000 to 270,000 grams of processed, oil-based extracts per month, making Swell one of the largest processing groups in Oregon. Additionally, a new state-of-the-art facility located in Bend, Ore., will be operational in December, adding a further capacity to process 1,200 lbs of raw material per month delivering a further 65,000 grams of processed high-quality extracts monthly.
"Swell is C21 Investment's fourth U.S. operation within its asset portfolio to sign a definitive agreement," said Robert Cheney, president and CEO of C21 Investments. "Acquiring Swell fulfills a critical segment in the company's expansion strategy making C21 Investments a leading force in processing and manufacturing in the United States."
"Consumption of cannabis concentrates, such as vapes and edibles, saw a 49-percent increase in 2018," said Alleh Lindquist, CEO of Swell. "This segment is quickly becoming the most significant component in cannabis consumption and with the support of C21, Swell will have the necessary resources to further expand its extraction and manufacturing capabilities to new markets."
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
Get the cannabis/hemp stock directory as an Investor ideas member, plus get weekly updates with new pot stocks added and get the daily potcast for Investor Ideas #Potcasts #Cannabis News and Stocks on the Move. Learn more https://www.investorideas.com/membership/
Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and sector trends from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto, technology including AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts#Cannabis News and Stocks on the Move podcast and column and the Cleantech and Climate Change Podcast.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp. Learn more about Investor ideas podcast and news publication services and costs https://www.investorideas.com/News-Upload/
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: https://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
#Cannabis Delivery Technology Stock News from The Greater Cannabis Company (OTC: $GCAN), Aphria (TSX: $APHA.TO) (NYSE: $APHA), Tilray ( $TLRY), Aurora (TSX: $ACB.TO) (NYSE: $ACB) and Canopy Growth (TSX: $WEED.TO) (NYSE: $CGC)
Point Roberts, WA and Kelowna, BC - November 5, 2018 (Investorideas.com Newswire) Cannabis Delivery Technology Stock News - Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks releases a sector snapshot with a focus on new and innovative delivery systems coming to market.
Through the month of September, larger Canadian cannabis companies including Aphria Inc. (TSX: APHA.TO), which commences trading on the NYSE today (NYSE: APHA), have been investing heavily in new cannabis delivery systems. These technologies have the ability to afford consumers a safer alternative to other routes of cannabinoid delivery, many of which have detrimental health effects.
The global trend is in play in the U.S as well. This past Wednesday, The Greater Cannabis Company, Inc. (OTC: GCAN), a biopharmaceutical company focused on development and commercialization of innovative delivery systems for the Cannabis market, announced "the completion of development and reformulation of its eluting patch (EPP) for cannabinoid use. The EPP has been successfully developed in the past for pharmaceutical and over the counter (OTC) products, as well as for oral health applications. In preparation for commercializing cannabinoid products, the Company completed extensive testing of its new formulations. The cannabinoid transmucosal patch was found to have additional benefits over those previously mentioned, and which can be found on the Company's website. GCAN's product allows consumers to absorb cannabinoids through the vascular buccal mucosa (cheek) directly into the bloodstream, and bypass the GI tract. They look like Listerine fresh breath strips, but instead of melting in your mouth right away they have bioadhesive properties that allow the thin films to unobtrusively stick to the inside of your mouth. The cannabinoid actives loaded on the thin films absorb through the very vascular oral cavity and go right into the bloodstream. The unique delivery system also has a mechanism that allows for an initial rapid release of CBD/THC followed by a slow and gradual release of the cannabinoids on subsequent layers of the same thin film. The intent behind the fully dissolvable patch is to offer consumers a needle-free systemic delivery of cannabinoids, while effectively bypassing the digestive and hepatic systems, and without the side effects typically found with smoking or vaping."
"The Company has entered into a new stage of aggressively ramping up its efforts to commercialize the technology through sublicensing and joint venture agreements. Target partners include licensed producers and dealers in the United States, Canada and abroad, as well as pharmaceutical companies focused on cannabinoids therapies."
According to the company's news - "New delivery systems are making their way into the industry. By way of example - the industry is fast adopting similar delivery technologies as seen in recent transactions."
Standardized and controlled dosing is driving cannabis companies strategic direction, and what may been fueling many of these delivery system transactions. This new and innovative U.S. company (OTC: GCAN) is correct and right on the money in not only seeing the trend, but participating in it.
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB.TO ) announced it acquired an equity stake in CTT Pharmaceutical Holdings Inc. back in September of this year, converting the $1,000,000 USD/5% debenture into equity shares of CT, giving an approximate 9.14% equity ownership stake in CTT while still holding a warrant which enables Aurora to increase its equity ownership to 42.5%. CTT's principal asset is a unique and novel patented drug delivery technology, an orally administered, fast-dissolving, thin film (the "Wafer"). This technology platform will target both the human and veterinary (pet) markets for treatment of many diseases. The Company believes that its Wafer technology will be one of the first to gain use in major markets such as pain management. Several Canadian and U.S. patents protect the Oral Thin Film (Wafer) formulation.
From the news, "CTT's oral fast dissolving drug delivery systems consist of edible Wafers that dissolve without water and within a few seconds after placement in the mouth. The majority of drugs administered using our drug delivery system mirror injections in that they have the ability to enter the bloodstream quickly, are convenient and discrete, and can be administered anywhere. A faster absorption rate is achieved because the mouth contains a very thin mucosa and is extremely vascular. There is no smoke inhalation, less degradation of medication (by bypassing the stomach) and most importantly lower dosage units are required given the efficacy of absorption. Patient compliance is also improved especially with those who have a fear of choking or difficulty swallowing, and/or are pediatric, geriatric or incapacitated."
Also in September, IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) announced that it had executed a non-binding letter of intent with Tilray, Inc.( NASDAQ: TLRY) to co-develop and commercialize oral film products infused with recreational and medical cannabis ("cannabis-infused VersaFilm™"), in anticipation of amended cannabis regulations which would allow adult-use consumers to purchase edible products.
"Through the company's work on VersaFilm with Tilray, IntelGenx Corp has also developed new products out of this technology, specifically RIZAPORT. The company recently announced that its commercialization partner for RIZAPORT® (10mg) in Spain, Groupo Juste, which is now part of Exceltis Healthcare, has received national marketing authorization from the Spanish Agency of Medicines and Medical Devices (AEMPS) for the product."
"RIZAPORT® is a proprietary oral thin film formulation of rizatriptan for the treatment of acute migraines. RIZAPORT® offers an innovative and potentially advantageous therapeutic alternative for many migraine patients, primarily patients who suffer from dysphagia or migraine-related nausea, due to its convenient dosing, facile intake due to the lack of need for water, and neutral flavor."
Continuing that same September delivery trend, CURE Pharmaceutical (OTC: CURR) announced that "it entered into a multi-year licensing agreement for the first time with a leading international cannabis company, Canopy Growth (NYSE: CGC) (TSX: WEED.TO). Under the terms of the agreement, the cannabis company will have an exclusive license to CURE's patented, multi-layer oral thin film (OTF) CUREfilm technology for use with cannabis extracts and biosynthetic cannabinoids in markets around the world."
"Whole plant extracted, biosynthesized and synthetic cannabinoids all hold therapeutic promise for given indications and intended uses," said Rob Davidson, CEO and chairman of CURE Pharmaceutical. "At CURE, we focus on synthetic cannabinoids for CUREfilm products, but with our new licensing business model, we will expand the impact and applications of our technology to these other promising approaches by partnering with an industry leader in this market."
Aphria Inc. (TSX: APH) (NYSE: APHA) was no exception to the move of big cannabis companies buying into cannabis delivery systems. Aphria and Rapid Dose Therapeutics Inc., a Canadian bio-technology company focused on innovative drug delivery solutions, announced as well in September that they have "signed a non-binding Memorandum of Understanding related to RDT's QuickStrip™ products. Under the terms of the MOU, the companies intend to enter into a definitive agreement in the near future pursuant to which RDT will provide Aphria with exclusive global preferred rights to produce, distribute and sell QuickStrip™ products for cannabis markets around the world."
According to their news, "Aphria is committed to bringing breakthrough innovations to the global cannabis market, which is why we are excited to introduce RDT as a strategic innovation partner," said Jakob Ripshtein, Chief Commercial Officer at Aphria. "They have developed a truly innovative product that will offer both patients and consumers a new way to consume and experience cannabis. We eagerly anticipate launching QuickStrip™ delivery technology across our portfolio of medical and adult-use brands and look forward to extending this valuable partnership to other markets around the world."
Seeing the amount of deal flow in the sector, the CEO is ramping up the roll-out for The Greater Cannabis Company, Inc. (OTC: GCAN). The Company's sole focus now is to bring its licensed technology to market. "The technology has the ability to afford consumers a safer alternative to other routes of cannabinoid delivery, many of which have detrimental health effects. As part of its strategic initiative, the Company is seeking to expand its sales team with the intent to grow deal flow, and accelerate the sales cycle."
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and sector trends from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto, technology including AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts#Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change Podcast and the AI Eye Podcast and column covering developments in AI.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp. Disclosure: this article featuring GCAN is a paid for article at Investorideas.com - learn more about costs and services https://www.investorideas.com/News-Upload/
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: https://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
New #CannabisStocks Added to Investor Ideas Directory; (CSE: $CNVC.C), (OTC: $GCAN) (TSXV: $PAS.V)
Point Roberts, WA and Delta, BC - November 2, 2018 (Investorideas.com Newswire) Investorideas.com, a global news source and investor resource covering cannabis and hemp stocks announces this week's additions to its cannabis /hemp stock directory for investors following the sector.
Investorideas.com tracks cannabis and hemp stocks on the TSX, TSX.V, CSE, OTC, NYSE, NASDAQ, ASX and global stock exchanges and makes ongoing additions to its stock directories for its follower and members.
This week's new companies are all involved in the technical/biotech aspect of the cannabis industry with focuses on plant cell growth in bioreactors, Cannabinoid delivery systems, without the harmful side effects and cancer treatment which includes cannabinoid-based therapeutics, respectively.
Canna-V-Cell Sciences Inc. (CSE: CNVC) -; formerly Midnight Star Ventures - is a scientific research company which has licensed a proprietary technology for growing plant cells in bioreactors for cannabis purposes. The company is completing research and development to adapt the technology to cannabis. It also has an option to acquire an eighty percent (80%) interest in the Fish Project (the "Fish Project"). The Fish Project is comprised of 56 unpatented mining claims covering approximately 1,120 acres located in Esmeralda County, Nevada.
Greater Cannabis Company, The (OTC:GCAN) is a biotechnology company focused on the development and commercialization of innovative Cannabinoid delivery systems. Greater Cannabis deploys its licensed, patented technology platform for use in the Cannabis industry. The Company's conveyance platform can be utilized to deliver Cannabinoids without the harmful side effects found with other routes of Cannabinoid administration. The technology is versatile in that for the first-time patients can receive lower dosing, enhanced bioavailability, and controlled rapid and delayed release using a fully dissolvable, non-irritant oral eluting patch. Greater Cannabis' mission is to bring our technology to the global market through partnerships with leading Cannabis and pharmaceutical companies, for the benefit of patients and consumers.
Pascal Biosciences Inc. (TSX.:PAS.V) is a biotechnology company focused on advancing innovative approaches for the treatment of cancer including cannabinoid-based therapeutics and targeted therapies. The company's leading cannabinoid portfolio comprises a small molecule therapeutic, ST-403, that is advancing into clinical trials for the treatment of glioblastoma, and an immuno-stimulatory molecule. In addition, Pascal Biosciences is developing a B-cell targeted antibody for acute lymphoblastic leukemia and an antibody for calcium channels expressed by the immune system
For investors following the sector Investor Ideas has created a stock directory of publicly traded CSE, TSX, TSXV, OTC, NASDAQ, NYSE, ASX Marijuana / Hemp Stocks. Visit directory.
Investorideas.com global stock directories are part of the membership program on the site, accessed either by login and password or available in PDF format. The directories include stocks trading on the TSX, OTC, NASDAQ, NYSE and other recognized global stock exchanges, giving retail investors a wide variety of stocks to review. https://www.investorideas.com/membership/
The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and sector trends from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto, technology including AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts#Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change Podcast and the AI Eye Podcast and column covering developments in AI.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer and disclosure info: https://www.investorideas.com/About/Disclaimer.asp.
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: https://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
